MENU
CRON
AS OF
Feb 6 closing price
Price
$2.64
Change
+$0.08 (+3.12%)
Capitalization
1.01B
24 days until earnings call
Intraday BUY SELL Signals
Go to the list of all blogs
Anna G's Avatar
published in Blogs
Feb 22, 2022
Cronos (CRON, $3.53) beats quarterly earnings expectations

Cronos (CRON, $3.53) beats quarterly earnings expectations

Cronos Group reported  its quarterly earnings that surpassed analysts’ expectations.

 The cannabis research company’s earnings came in at $0.21 per share for the quarter, beating the Zacks' consensus estimate of $0.13.  Earnings in the prior-year quarter were $0.19 a share.

Revenue rose +79.6% from the year-ago quarter to $20.40 million, compared to analysts' expectations of $23.03 million.

Cronos Group had a negative net margin of 258.59% and a negative return on equity of 9.48%.

Related Ticker: CRON

CRON sees its Stochastic Oscillator ascending out of oversold territory

On February 04, 2026, the Stochastic Oscillator for CRON moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 81 instances where the indicator left the oversold zone. In of the 81 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRON as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CRON turned negative on January 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .

CRON moved below its 50-day moving average on January 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRON crossed bearishly below the 50-day moving average on January 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRON broke above its upper Bollinger Band on January 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRON entered a downward trend on January 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.934) is normal, around the industry mean (25.254). P/E Ratio (24.000) is within average values for comparable stocks, (77.551). CRON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.058). CRON has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (7.645) is also within normal values, averaging (112.123).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.77B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 13%. LVRLF experienced the highest price growth at 599%, while PRFX experienced the biggest fall at -83%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was 9% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 59
SMR Rating: 80
Profit Risk Rating: 90
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
CRON
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CRON showed earnings on November 06, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

pharmaceutical, medical marijuana, cannabis

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
111 Peter Street
Phone
+1 416 504-0004
Employees
447
Web
https://www.thecronosgroup.com
Interact to see
Advertisement
In the fast-paced world of stock trading, where market volatility can make or break fortunes, AI trading bots are emerging as game-changers.
#artificial_intelligence
In today's dynamic stock market, where alternative assets and financial services are booming, AI trading bots are revolutionizing how investors approach opportunities.
Introduction to AI-Driven Trading Evolution The integration of AI into financial markets has transformed trading from a labor-intensive, intuition-driven process into a data-driven, automated endeavor.
#artificial_intelligence
The financial markets are a dynamic arena where precision, speed, and adaptability define success. Tickeron, a leader in AI-powered trading solutions, has redefined the landscape with its innovative AI Trading Double Agent, achieving a remarkable 10 out of 12 profitable trades in a 5-minute trading strategy for Monolithic Power Systems (MPWR) and Direxion Daily Semiconductor…
Introduction: FLMs Enter a New Era of Market Agility As of August 2025, the AI-powered trading landscape is undergoing a powerful transformation. Tickeron’s latest Financial Learning Models (FLMs) have rapidly advanced in both speed and intelligence, enabling the platform to introduce two new categories of AI Trading Signal Agents operating on ultra-short 5-minute and 15-minute…
In the dynamic world of financial markets, artificial intelligence (AI) has emerged as a transformative force, redefining trading strategies with unprecedented precision and efficiency.
#artificial_intelligence
The financial markets of 2025 are characterized by rapid volatility, driven by macroeconomic shifts, technological advancements, and evolving investor sentiment. Tickeron, a leading financial technology company, has emerged as a trailblazer in this landscape by deploying AI Trading Agents that leverage advanced Financial Learning Models (FLMs) to deliver precision, adaptability, and superior returns.
#artificial_intelligence
In the ever-evolving landscape of stock trading, where technology sectors like semiconductors and wireless communications drive innovation, AI trading bots are becoming essential allies for investors.
#artificial_intelligence
As stock markets continue to surge with infrastructure demands, AI trading bots are transforming how investors harness opportunities in sectors like energy and utilities. These intelligent AI systems process real-time data, uncover hidden patterns, and automate decisions, making them a boon for beginners and a strategic asset for experienced traders.
#artificial_intelligence#trading
The financial markets in 2025 are a battleground of volatility, opportunity, and technological innovation.
#artificial_intelligence
The financial landscape over the past decade has witnessed an extraordinary evolution, particularly with the rise of cryptocurrencies like Ethereum and Bitcoin
#artificial_intelligence
Bollinger Innovations, Inc. (BINI), formerly known as Mullen Automotive, Inc., has experienced a catastrophic decline in its stock price throughout 2025, losing a staggering 98.19% of its value year-to-date, with an average daily trading volume of 161,610 shares.
#artificial_intelligence
Bollinger Innovations, Inc. (BINI), formerly known as Mullen Automotive, Inc., has experienced a catastrophic decline in its stock price throughout 2025, losing a staggering 98.19% of its value year-to-date, with an average daily trading volume of 161,610 shares.
#artificial_intelligence
In the rapidly evolving landscape of financial markets, artificial intelligence (AI) has emerged as a transformative force, redefining trading efficiency and profitability.
#artificial_intelligence
The financial markets in 2025 are defined by volatility, driven by technological advancements, geopolitical shifts, and macroeconomic uncertainties.
Outline Introduction: Tickeron Advances AI Trading with FLMs and Rapid-Reaction Agents Tickeron, a leading fintech innovator, has rolled out a groundbreaking evolution in algorithmic trading. Built upon robust, proprietary Financial Learning Models (FLMs), Tickeron’s newly deployed AI Trading Agents operating on ultra-short 15-minute and 5-minute machine-learning time frames demonstrate exceptional performance.
#artificial_intelligence
As of August 09, 2025, the financial landscape continues to showcase the dynamic rivalry between Apple Inc. (AAPL) and Tesla, Inc. (TSLA), two titans representing distinct sectors of the technology and automotive industries.
#artificial_intelligence
As of August 9, 2025, the financial landscape presents an intriguing comparison between Meta Platforms Inc. (META) and NVIDIA Corporation (NVDA), two titans in their respective industries.
#artificial_intelligence
Tickeron’s recent strides in deploy­ing AI Trading Agents built on shorter ML cycles have produced striking returns—+204% annualized on NVDA (15 min), +112% on AVGO (15 min), and +106% on KKR (5 min).
#artificial_intelligence#trading